Table 2: Oxidative stress markers in G6PD deficient cancer patients.

GROUP            

N

MDA (nmol/ml)

TPP (µmol/L)

TAP (µmol /L)

OSI

A

24

0.977 ± 0.0379

99.664 ± 7.659

190.861 ± 18.456

69.508 ± 17.707

B

36

0.972 ± 0.4797

92.779 ± 6.351

189.438 ± 13.255

51.843 ± 4.057

C

15

0.938 ± 0.0398

88.938 ± 4.985

232.463 ± 22.660

44.407 ± 4.526

D

25

0.911 ± 0.043

80.202 ± 5.044

244.086 ± 18.097

39.923 ± 3.599

p value

 

p > 0.05

p > 0.05

p > 0.05

p > 0.05

POST HOC

A vs. B

 

p > 0.05

p > 0.05

 p > 0.05

p > 0.05

A vs. C

 

p > 0.05

p > 0.05

p > 0.05

p > 0.05

A vs. D

 

p > 0.05

p > 0.05

p > 0.05

p > 0.05

B vs. C

 

p > 0.05

p < 0.05*

p > 0.05

p < 0.05*

B vs. D

 

p > 0.05

p > 0.05

p < 0.05*

p < 0.05*

Group A = Cancer patients with G6PD deficiency, Group B = Cancer patients with normal G6PD status, Group C = Control subjects with G6PD deficiency and Group D = Control subjects with normal G6PD status, p < 0.05= significant.